{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:10:56Z","timestamp":1791839456407,"version":"4.3.4"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Prostate cancer remains the most common cancer and the second leading cause of cancer-related mortality among men in the United States. Despite advances in therapy, relapses and progression of disease continue to pose major clinical challenges, underscoring the need for innovative strategies. A decade ago, we reviewed the emerging evidence linking Toll-like receptors (TLRs), a family of innate immune sensors, to prostate cancer initiation and progression. Since then, substantial advances have deepened our understanding of TLR biology in prostate cancer, revealing their role in either promoting tumor growth or activating anti-tumor immunity depending on cellular context and signaling pathways. Recent studies have expanded knowledge of TLR expression on both immune and tumor cells, identified key endogenous ligands driving chronic inflammation, and uncovered microRNA-mediated regulation of TLR signaling. Moreover, new insights into TLR polymorphisms and their potential association with cancer risk, as well as preclinical and clinical progress in TLR-targeted immunotherapies, highlight both opportunities and challenges in translating TLR biology into therapeutic applications. In this review, we update the field by summarizing the latest discoveries, evaluating the complexities of TLR signaling in prostate cancer, and discussing how this evolving knowledge may inform future biomarker development and immunotherapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1711815","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:57:19Z","timestamp":1768204639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights"],"prefix":"10.3389","volume":"16","author":[{"given":"Jahnavi","family":"Janjirala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dekai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00602-5","article-title":"Cancers make their own luck: theories of cancer origins","volume":"23","author":"Jassim","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189229","article-title":"Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer","volume":"1880","author":"Khan","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408363.2018.1517144","article-title":"Bacterial imbalance and gut pathologies: Association and contribution of E. coli in inflammatory bowel disease","volume":"56","author":"Khan","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8306","article-title":"Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology","volume":"8","author":"Khan","year":"2017","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-4970-9","article-title":"Computational prediction of Mycoplasma hominis proteins targeting in nucleus of host cell and their implication in prostate cancer etiology","volume":"37","author":"Khan","year":"2016","journal-title":"Tumour Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0148530","DOI":"10.1371\/journal.pone.0148530","article-title":"Systems biology approaches for the prediction of possible role of chlamydia pneumoniae proteins in the etiology of lung cancer","volume":"11","author":"Khan","year":"2016","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/jca.63517","article-title":"Decipher the Helicobacter pylori Protein Targeting in the Nucleus of Host Cell and their Implications in Gallbladder Cancer: An insilico approach","volume":"12","author":"Wang","year":"2021","journal-title":"J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.05.002","article-title":"Potential role of Escherichia coli DNA mismatch repair proteins in colon cancer","volume":"96","author":"Khan","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22115421","article-title":"Inflammation-induced tumorigenesis and metastasis","volume":"22","author":"Hibino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24756","article-title":"Influence of microbiome in intraprostatic inflammation and prostate cancer","volume":"84","author":"Prakash","year":"2024","journal-title":"Prostate"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00352","article-title":"Toll-like receptors and prostate cancer","volume":"5","author":"Zhao","year":"2014","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/sqb.1989.054.01.003","article-title":"Approaching the asymptote? Evolution and revolution in immunology","author":"Janeway","year":"1989","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11193127","article-title":"Of flies and men-the discovery of TLRs","volume":"11","author":"Weiss","year":"2022","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and innate immunity","volume":"113","author":"Beutler","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00516","article-title":"Recognition of double-stranded RNA and regulation of interferon pathway by toll-like receptor 10","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000524461","article-title":"Regulation of TLR10 expression and its role in chemotaxis of human neutrophils","volume":"14","author":"Balachandran","year":"2022","journal-title":"J Innate Immun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15123110","article-title":"The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer","volume":"15","author":"Oseni","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1\u201310 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13747","article-title":"Linking infection and prostate cancer progression: toll-like receptor3 stimulation rewires glucose metabolism in prostate cells","volume":"39","author":"Magnifico","year":"2019","journal-title":"Anticancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells13010097","article-title":"TLR9 monotherapy in immune-competent mice suppresses orthotopic prostate tumor development","volume":"13","author":"Miles","year":"2024","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2022.05.009","article-title":"Toll-like receptor 3 overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis","volume":"192","author":"Muresan","year":"2022","journal-title":"Am J Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12379","article-title":"TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo","volume":"19","author":"Gambara","year":"2015","journal-title":"J Cell Mol Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15030757","article-title":"Innate immune program in formation of tumor-initiating cells from cells-of-origin of breast, prostate, and ovarian cancers","volume":"15","author":"Han","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092524","article-title":"Influence of intratumor microbiome on clinical outcome and immune processes in prostate cancer","volume":"12","author":"Ma","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24545","article-title":"Upregulation of TLR5 indicates a favorable prognosis in prostate cancer","volume":"83","author":"Liang","year":"2023","journal-title":"Prostate"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155379","article-title":"Toll-like receptor (TLR) 4 is a potent prognostic factor in prostate cancer associated with proliferation and invasion","volume":"260","author":"Takahashi","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaa046","article-title":"Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target","volume":"3","author":"Greulich","year":"2021","journal-title":"NAR Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1008647","article-title":"The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer","volume":"86","author":"Ehrchen","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12885-021-07850-4","article-title":"The role of S100A4 for bone metastasis in prostate cancer cells","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life12101489","article-title":"Heat shock protein 70 and 90 family in prostate cancer","volume":"12","author":"Fu","year":"2022","journal-title":"Life (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.02112.x","article-title":"Heat shock up-regulates expression of Toll-like receptor-2 and Toll-like receptor-4 in human monocytes via p38 kinase signal pathway","volume":"114","author":"Zhou","year":"2005","journal-title":"Immunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16073","DOI":"10.1038\/s41598-023-43427-w","article-title":"Coagulation markers as independent predictors of prostate cancer aggressiveness: a retrospective cohort study","volume":"13","author":"Lei","year":"2023","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/08923973.2020.1725040","article-title":"Anti-inflammatory effects of nobiletin on TLR4\/TRIF\/IRF3 and TLR9\/IRF7 signaling pathways in prostate cancer cells","volume":"42","author":"Deveci Ozkan","year":"2020","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06953-2","article-title":"Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro","volume":"49","author":"Deveci Ozkan","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0931-0","article-title":"Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence","volume":"60","author":"Gonzalez-Reyes","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s44318-024-00040-5","article-title":"Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB\/IRF3 activation promotes antitumor immunity in prostate cancer","volume":"43","author":"Alaimo","year":"2024","journal-title":"EMBO J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2907256","article-title":"Associations of CYLD, JAK2 and TLR4 genotypes with PSA levels and immunophenotype in benign prostatic hyperplasia and prostate cancer","volume":"29","author":"Duy","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0688-7","article-title":"Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8\/miR21 axis","volume":"38","author":"Comito","year":"2019","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12229","article-title":"MicroRNA-155 deficiency attenuates inflammation and oxidative stress in experimental autoimmune prostatitis in a TLR4-dependent manner","volume":"36","author":"Fu","year":"2020","journal-title":"Kaohsiung J Med Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy089","article-title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","volume":"29","author":"Rodriguez-Ruiz","year":"2018","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3693","article-title":"Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer","volume":"31","author":"Galsky","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03024-0","article-title":"Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial","volume":"70","author":"Filaci","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/0960327120984209","article-title":"Association between the anticancer efficacy of cabazitaxel and toll-like receptor 4 mediating signaling pathways in metastatic castration-resistant prostate cancer cells","volume":"40","author":"Guney Eskiler","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154673","article-title":"Implications of Toll-like receptors (TLRs) and their signaling mechanisms in human cancers","volume":"248","author":"Chandrasekar","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics14112285","article-title":"Immunotherapeutic implications of toll-like receptors activation in tumor microenvironment","volume":"14","author":"Zheng","year":"2022","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms25169053","article-title":"Serum TLR2 and TLR9 in prostate cancer patients in relation to EBV status","volume":"25","author":"Sikora","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_100_18","article-title":"Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells","volume":"21","author":"Fan","year":"2019","journal-title":"Asian J Androl"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2022.01.005","article-title":"Exosome-mediated delivery of transforming growth factor-beta receptor 1 kinase inhibitors and toll-like receptor 7\/8 agonists for combination therapy of tumors","volume":"141","author":"Lee","year":"2022","journal-title":"Acta Biomater"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27549","article-title":"First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients","volume":"11","author":"Eremina","year":"2020","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph18060804","article-title":"Performance of imidazoquinoline glycoconjugate BAIT628 as a TLR7 agonist prodrug for prostate cancer","volume":"18","author":"Najibi","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1304610110","article-title":"Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARbeta and tumor regression","volume":"110","author":"Galli","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41419-018-1092-x","article-title":"miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis","volume":"9","author":"Shi","year":"2018","journal-title":"Cell Death Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180800","article-title":"TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG","volume":"215","author":"Zhang","year":"2018","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4029","article-title":"TLR9 signaling through NF-kappaB\/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells","volume":"6","author":"Moreira","year":"2015","journal-title":"Oncotarget"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.06.016","article-title":"Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity","volume":"46","author":"Hua","year":"2009","journal-title":"Mol Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.906857","article-title":"Toll-like receptor 4 (TLR4)\/cyclooxygenase-2 (COX-2) regulates prostate cancer cell proliferation, migration, and invasion by NF-kappaB activation","volume":"24","author":"Wang","year":"2018","journal-title":"Med Sci Monit"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-009-9620-5","article-title":"Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells","volume":"37","author":"Di","year":"2010","journal-title":"Mol Biol Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0007","article-title":"Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity","volume":"4","author":"Merrell","year":"2006","journal-title":"Mol Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S28683","article-title":"Are Toll-like receptor gene polymorphisms associated with prostate cancer","volume":"4","author":"Kutikhin","year":"2012","journal-title":"Cancer Manag Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm14070753","article-title":"Inflammatory response genes\u2019 Polymorphism associated with risk of rheumatic heart disease","volume":"14","author":"Sinitskaya","year":"2024","journal-title":"J Pers Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-3280","article-title":"Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study","volume":"64","author":"Zheng","year":"2004","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2078","article-title":"Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0429","article-title":"Toll-like receptor 4 genetic variation and advanced prostate cancer risk","volume":"16","author":"Cheng","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cancergencyto.2008.12.011","article-title":"The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men","volume":"190","author":"Song","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20933","article-title":"Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II","volume":"69","author":"Wang","year":"2009","journal-title":"Prostate"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0690-3","article-title":"Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men","volume":"30","author":"Kim","year":"2012","journal-title":"World J Urol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji070","article-title":"Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk","volume":"97","author":"Sun","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23826","article-title":"Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk","volume":"123","author":"Stevens","year":"2008","journal-title":"Int J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21423","article-title":"Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality","volume":"72","author":"Shui","year":"2012","journal-title":"Prostate"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-0325","article-title":"Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer","volume":"16","author":"Chen","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0618","article-title":"Sequence variants in the TLR4 and TLR6-1\u201310 genes and prostate cancer risk. Results based on pooled analysis from three independent studies","volume":"19","author":"Lindstrom","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e110569","DOI":"10.1371\/journal.pone.0110569","article-title":"Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis","volume":"9","author":"Weng","year":"2014","journal-title":"PLoS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-015-0020-z","article-title":"TLR3 gene polymorphisms in cancer: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2015","journal-title":"Chin J Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24067","article-title":"Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men","volume":"80","author":"Dubey","year":"2020","journal-title":"Prostate"},{"key":"B77","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4161\/onci.20931","article-title":"Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70324-2","article-title":"Success of HPV vaccination is now a matter of coverage","volume":"13","author":"Schiffman","year":"2012","journal-title":"Lancet Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03200.x","article-title":"Successful treatment of perianal Bowen\u2019s disease with imiquimod","volume":"46","author":"van Egmond","year":"2007","journal-title":"Int J Dermatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22033","article-title":"How imiquimod licenses plasmacytoid dendritic cells to kill tumors","volume":"1","author":"Holcmann","year":"2012","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting Toll-like receptors: emerging therapeutics","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.001073","article-title":"Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer","volume":"61","author":"O\u2019Neill","year":"2009","journal-title":"Pharmacol Rev"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1898","article-title":"In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod","volume":"42","author":"Han","year":"2013","journal-title":"Int J Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12146","article-title":"TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells","volume":"70","author":"Han","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn149","article-title":"Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism","volume":"29","author":"Paone","year":"2008","journal-title":"Carcinogenesis"},{"key":"B88","article-title":"Clinical studies with ampligen (mismatched double-stranded RNA)","volume":"4","author":"Brodsky","year":"1985","journal-title":"J Biol Response Mod"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1415-9","article-title":"A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer","volume":"62","author":"Fenoglio","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-012-9221-2","article-title":"Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells","volume":"28","author":"Zhang","year":"2012","journal-title":"Cell Biol Toxicol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.346","article-title":"Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy","volume":"37","author":"Mett","year":"2018","journal-title":"Oncogene"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1711815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:57:20Z","timestamp":1768204640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1711815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2025.1711815"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1711815","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1711815"}}